Compare FPF & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | CDNA |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | FPF | CDNA |
|---|---|---|
| Price | $17.98 | $20.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 83.5K | ★ 598.1K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $399.00 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $17.21 | $10.96 |
| 52 Week High | $19.75 | $23.24 |
| Indicator | FPF | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 51.42 |
| Support Level | $17.21 | $16.63 |
| Resistance Level | $18.71 | $21.42 |
| Average True Range (ATR) | 0.19 | 1.35 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 10.34 | 48.05 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.